HealthPartners Institute, 8170 33rd Ave S, MS21112R, Minneapolis, MN, 55425, United States of America.
Geisinger Health, 100 North Academy Ave., Danville, PA 17822, United States of America.
Contemp Clin Trials. 2023 Jan;124:107012. doi: 10.1016/j.cct.2022.107012. Epub 2022 Nov 17.
Opioid-related deaths continue to rise in the U.S. A shared decision-making (SDM) system to help primary care clinicians (PCCs) identify and treat patients with opioid use disorder (OUD) could help address this crisis.
In this cluster-randomized trial, primary care clinics in three healthcare systems were randomized to receive or not receive access to an OUD-SDM system. The OUD-SDM system alerts PCCs and patients to elevated risk of OUD and supports OUD screening and treatment. It includes guidance on OUD screening and diagnosis, treatment selection, starting and maintaining patients on buprenorphine for waivered clinicians, and screening for common comorbid conditions. The primary study outcome is, of patients at high risk for OUD, the percentage receiving an OUD diagnosis within 30 days of index visit. Additional outcomes are, of patients at high risk for or with a diagnosis of OUD, (a) the percentage receiving a naloxone prescription, or (b) the percentage receiving a medication for OUD (MOUD) prescription or referral to specialty care within 30 days of an index visit, and (c) total days covered by a MOUD prescription within 90 days of an index visit.
The intervention started in April 2021 and continues through December 2023. PCCs and patients in 90 clinics are included; study results are expected in 2024.
This protocol paper describes the design of a multi-site trial to help PCCs recognize and treat OUD. If effective, this OUD-SDM intervention could improve screening of at-risk patients and rates of OUD treatment for people with OUD.
在美国,阿片类药物相关死亡人数持续上升。一个帮助初级保健临床医生(PCC)识别和治疗阿片类药物使用障碍(OUD)患者的共同决策(SDM)系统可能有助于解决这一危机。
在这项聚类随机试验中,三个医疗系统的初级保健诊所被随机分配接受或不接受阿片类药物使用障碍-SDM 系统的访问权限。该 OUD-SDM 系统提醒 PCC 和患者注意 OUD 风险升高,并支持 OUD 筛查和治疗。它包括 OUD 筛查和诊断、治疗选择、为豁免临床医生启动和维持患者使用丁丙诺啡、以及筛查常见合并症的指南。主要研究结果是,在高风险 OUD 的患者中,在索引就诊后 30 天内接受 OUD 诊断的百分比。其他结果是,在高风险或已诊断为 OUD 的患者中,(a)接受纳洛酮处方的百分比,或(b)在索引就诊后 30 天内接受 OUD 药物(MOUD)处方或转介至专科治疗的百分比,以及(c)索引就诊后 90 天内 MOUD 处方覆盖的总天数。
干预措施于 2021 年 4 月开始,持续到 2023 年 12 月。90 家诊所的 PCC 和患者均包括在内;预计研究结果将于 2024 年公布。
本文描述了一项多地点试验的设计,旨在帮助 PCC 识别和治疗 OUD。如果有效,这种 OUD-SDM 干预措施可以改善高危患者的筛查,并提高 OUD 患者的 OUD 治疗率。